Amylin Pharmaceuticals Inc. is preparing for a second round of bids after attracting offers that value the diabetes drugmaker at $25 to $29 per share, said people with knowledge of the process. AstraZeneca PLC joined Sanofi, Merck & Co. and Bristol-Myers Squibb Co. in making first-round proposals, said the people, who declined to be identified as talks are private. Pfizer Inc., which made a bid on the lower end of the range, is dropping out of the process, said one of the people.
